Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK, Daiichi Sankyo Vaccine Joint Venture Dissolved
April 2, 2019
- Mochida Aims at 108 Billion Yen Sales in FY2021: New 3-Year Biz Plan
April 2, 2019
- Pfizer, Mochida Tie Up for Antidepressant Desvenlafaxine in Japan
April 2, 2019
- Takeda Files Adcetris for PTCL, Pediatric Use in Japan
April 1, 2019
- Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change
April 1, 2019
- Safety Monitoring Board Backs PIII Continuation for Elenbecestat: Eisai
April 1, 2019
- Chugai Files for Gene Test for Companion Diagnostic to Lynparza
April 1, 2019
- Takeda Spin-Off Startup Chordia Raises 3 Billion Yen to Fund Oncology R&D
April 1, 2019
- Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease
March 29, 2019
- Janssen Files Stelara for Ulcerative Colitis in Japan
March 29, 2019
- Ono Seeks Japan Approval for Opdivo in MSI-H Colorectal Cancer
March 29, 2019
- Pfizer Japan to Stop Hiring Smokers
March 29, 2019
- Astellas/Seattle Genetics’ ADC Succeeds in PII Urothelial Cancer Study; US Filing Set for 2nd Half of 2019
March 29, 2019
- After 70% Pricing OK’ed for Biosame, Nesp Biosimilar Developers Stay Pat on November Listing Plans
March 28, 2019
- Ono Hooks Up with UK Charities in Cancer Immunotherapy
March 28, 2019
- Daiichi Sankyo Kicks Off Asia PIII for Mirogabalin
March 28, 2019
- Chugai’s SMA Drug Risdiplam Gets Orphan Status
March 28, 2019
- JSR Enters Strategic Partnership with Dutch Institute in Oncology Field
March 28, 2019
- Astellas’ Vasomotor Symptom Treatment Fezolinetant Smashes Primary Goals in US PIIb Study
March 28, 2019
- Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan
March 27, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…